Narsoplimab is a monoclonal antibody commercialized by Omeros, with a leading Phase III program in Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome). According to Globaldata, it is involved in 11 clinical trials, of which 5 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Narsoplimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Narsoplimab is expected to reach an annual total of $230 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Narsoplimab Overview

OMS-721 is under development for the treatment of thrombotic microangiopathies (TMAs) including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, steroid-dependent Immunoglobulin A- IgA nephropathy (Berger's disease), lupus nephritis, C3 glomerulopathy and membranous nephropathy including dense deposit disease. OMS-721 can be administered by subcutaneous and intravenous routes as a solution. The drug candidate is a human monoclonal antibody which targets MASP-2. It was also under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), wet macular degeneration, ischemia-reperfusion injury, myocardial infarction, ischemic stroke and diabetic neuropathy.

OMS-721 is also under development for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome causing coronavirus 2 (SARS-CoV-2).

Omeros Overview

Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

The operating loss of the company was US$173.6 million in FY2021, compared to an operating loss of US$170.3 million in FY2020. The net profit of the company was US$194.2 million in FY2021, compared to a net loss of US$138.1 million in FY2020.

For a complete picture of Narsoplimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.